[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aalborg University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":695},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,41,67,99,135,164,200,232,254,289,317,344,372,392,414,445,472,492,522,546,570,591,615,639,670],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100640064","exploring-biomarkers-in-the-heat-and-moisture-exchange-filters-100640064",false,"NCT07607977","Exploring Biomarkers in the Heat and Moisture Exchange Filters","HMEPRO","Inclusion Criteria:\n\n* ≥18 years, able to understand study information in Danish.\n* Admitted for elective surgery for non-malignant conditions with either intravenous or inhalation anaesthesia and invasive mechanical ventilation according to standard practice.\n* Expected invasive mechanical ventilation \\> 1 hour.\n* Possess legal capacity.\n* Informed, signed consent is obtained.\n\nExclusion Criteria:\n\n* Patients who are transferred to the ICU for continuous invasive mechanical ventilation after end of elective surgery.\n* Known chronic lung disease.","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","OBSERVATIONAL","When patients undergo major surgery, they are connected to a ventilator during anesthesia. A heat and moisture exchange filter (HME filter) is routinely placed in the ventilator tubing to ensure that the inhaled air is warm and humidified. Today, HME filters are used routinely in all ventilator treatments. They are typically replaced once a day and discarded as regular waste after use.\n\nThe purpose of this study is to investigate whether HME filters contain proteins and small biological particles from the patient's exhaled air.",[25],"Respiratory Inflammation",[27],"exhaled breath proteomics","RECRUITING","2026-05-19",{"date":31,"type":32},"2026-05-27","ACTUAL",{"date":34,"type":32},"2026-05-08",{"date":36,"type":21},"2027-05-01",{"name":38,"class":39},"Aalborg University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100637029","understanding-and-tailored-treatment-of-low-anterior-resection-syndrome-100637029","NCT07573371","Understanding and Tailored Treatment of Low Anterior Resection Syndrome","PATO-LARS","Inclusion Criteria:\n\nGeneral:\n\n* Must be able to read and understand Danish.\n* All participants must be adults and \\>18 years and have full legal capacity.\n* Assessed by study personnel to have understood the research protocol, being able to comply with investigation procedures as well as ability to come to the hospital at the agreed timepoints, and to complete the trial.\n\nSpecific inclusion criteria for LARS patients:\n\n* Patients operated for rectal cancer with a rectal resection and sphincter preserving surgery at a minimum of three months postop.\n* If patients have received a temporary protective ileostomy, this should have been reversed for a minimum of three months postop.\n\nSpecific inclusion criteria for fecal incontinence patients and urge fecal incontinence patients\n\n* Patients planned for neuromodulation.\n* Satisfactory interoperative test results leading to permanent implantation of a pacemaker for sacral nerve modulation.\n\nSpecific inclusion criteria for \"watch and wait\" patients:\n\n• Rectum\u002Fcolon cancer patients treated with organ-preserving treatment, i.e., chemotherapy and radiotherapy with a complete clinical and radiological response at a minimum of 12 months posttreatment.\n\nExclusion Criteria:\n\nGeneral exclusion criteria\n\n* Persons that are not able to understand information\n* Connective tissue disorders\n* Parkinson's disease\n* Non-MRI compatible pacemaker, clips or other metal objects in the body. Patients implanted with a pacemaker for sacral nerve modulation will not undergo MRI postoperatively.\n* Piercings that cannot be removed before MRI\n* Claustrophobia\n* Allergic to latex\n* Abdominal diameter equal or more than 140 cm\n* Have other individual factors, in the opinion of the physician\u002Fhealthcare professional, in which participating is contraindicated\n* Participation in concomitant clinical trial\n* Known intestinal obstruction, significant intestinal strictures or perforation. If in doubt about intestinal stricture, the patient will be examined with MRI of the small intestine, colonoscopy or other supplementing examination\n* Disorders of swallowing\n* Pregnant women\n\nSpecific exclusion criterias for LARS patients\n\n* History of anastomotic leakage following rectal resection and sphincter preserving therapy\n* Evidens of local recurrence or dessimination of the cancer",{"count":49,"type":21},145,"The goal of this observational study is to learn why some patients develop low anterior resection syndrome (LARS) after colorectal cancer treatment. The study also aims to identify different subtypes of LARS and understand which patients may respond to specific treatments.\n\nThe main questions it aims to answer are:\n\n* What physiological and imaging changes are associated with LARS?\n* How do patients with LARS differ from patients without LARS after colorectal cancer surgery?\n* Are there measurable differences between LARS, patients treated with organ-preserving chemoradiotherapy, and patients with fecal incontinence?\n\nParticipants will:\n\n* Complete advanced physiological and imaging assessments related to bowel function\n* Be compared with four control groups:\n\n  * patients without LARS after colorectal cancer surgery\n  * patients treated with organ-preserving chemoradiotherapy\n  * patients with fecal incontinence and urge fecal incontinence\n* Take part in a single study visit where all measurements are performed",[52,53,54,55],"Low Anterior Resection Syndrome","Faecal Incontinence With Faecal Urgency","Faecal Incontinence","Colorectal (Colon or Rectal) Cancer Survivors",[57],"LARS","2026-05-01",{"date":60,"type":32},"2026-05-07",{"date":62,"type":32},"2024-09-17",{"date":64,"type":21},"2026-12-31",{"name":38,"class":39},3,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100599148","phase-4-algorithm-guided-treatment-versus-treatment-as-usual-tau-for-patients-with-treatment-resistant-depression-100599148","NCT07080723","Algorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression","Inclusion Criteria:\n\n1. A diagnosis of unipolar depressive disorder according to ICD-10 based on documented completion of the Mini International Neuropsychiatric Interview, version 7.0.2 (MINI 7.0.2) at Screening and confirmed by medical records or a healthcare professional.\n2. Have not achieved stable remission of depression in 12 months at investigator's clinical assessment.\n3. Severity of depression: A score of at least 21 on the self-reported Major Depression Inventory (MDI).\n4. Age criteria: Subjects must be at least 18 years old and below 65 at the time of randomization.\n5. Signed document of informed consent.\n6. The participant is an outpatient.\n7. No significant change in medical treatment in the last 4 weeks before screening visit.\n8. The patient is pharmacologically treated for depression.\n\nExclusion Criteria:\n\n1. A diagnosis of dementia.\n2. Substance misuse influencing study participation as judged by the investigator.\n3. High risk of non-adherence at the investigator's discretion.\n4. Not understanding the Danish language as judged by the investigator.\n5. Suicidality according to C-SSRS with a positive response to question 4 or 5 within the last three months or upon investigator's discretion.\n6. Medical conditions such as cancer, kidney failure, epilepsy, deep brain stimulation device, or other medical conditions interfering with study the outcome and safety as judged by investigator's discretion.","65 Years",{"count":75,"type":21},80,"INTERVENTIONAL",[78],"PHASE4","The trial utilizes a pragmatic, randomized, open label design with two parallel arms. Participants aged 18-65 with a diagnosis of unipolar depressive disorder and without stable remission in the past 12 months are randomized 1:1 to receive either algorithm guided treatment (AGT) or treatment as usual (TAU). The AGT approach incorporates pre-defined treatment steps, critical decision points, and \"if-then\" rules based on symptom response. It leverages prior treatment history, current symptomatology, and tolerability profiles to personalize the therapeutic sequence and reduce treatment inertia. In contrast, TAU reflects standard clinical practice, where treatment decisions are left to clinician discretion without algorithmic structure. The primary objective of the study is to determine whether AGT leads to a greater reduction in depressive symptoms over a 12-week treatment period, as measured by the 6-item Hamilton Depression Rating Scale (HAMD-6). Secondary objectives include evaluating cognitive and psychosocial functioning, suicide risk, treatment adherence, tolerability, number of medication changes, and long-term outcomes at a 24-week follow-up, providing insights into the longer-term trajectory of TRD management.",[81],"Treatment Resistant Depression (TRD)",[83,84,85,86,87,88,89,90],"Algorithm guided treatment","AGT","ALGO","Treatment as usual","TAU","Treatment resistant depression","TRD","Depression","2026-04-24",{"date":93,"type":32},"2026-04-27",{"date":95,"type":32},"2025-08-13",{"date":97,"type":21},"2027-06",{"name":38,"class":39},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":121,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100634125","the-voided-urinary-perineal-and-faecal-microbiota-among-children-and-adolescents---the-ppuf-study-100634125","NCT07535619","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents - the PpUF-study.","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children and Adolescents - the PpUF-study.","Inclusion Criteria:\n\n* Overactive bladder as per International Children's Continence Society criteria (cases only).\n* At least two wet days per week (cases only).\n* No prior pharmacological treatment of OAB and DUI (cases only).\n* No lower urinary tract symptoms (healthy participants only).\n* Negative urine dipstick test\n\nExclusion Criteria:\n\n* No known urogenital abnormality affecting the lower urinary tract function.\n* No known gastrointestinal or neurological diseases.\n* No use of systemic drugs within five half-lives of the drug.\n* No use of systemic antibiotics within three months before inclusion\n* No current urinary tract infection.\n* No urinary tract infection within the last three months prior to inclusion.\n* No current constipation.\n* Abnormal uroflowmetry (healthy participants only).",true,"5 Years","17 Years",{"count":110,"type":21},110,"The aim of this study is to investigate whether the voided urinary, perineal\u002Fpreputial, and the fecal microbiota are different between children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the study aims to investigate if the microbiota is different according to the severity of DUI and if the microbiota is changed throughout treatment of DUI. A follow-up study will as well be performed on healthy children to investigate how the microbiota evolves with increasing age and pubertal stage. Children with OAB and DUI will be recruited from involved pediatric departments, and specimen in the form of urine, perineal\u002Fpreputial swabs, and feces will be collected according to the protocol.",[113,114,115,116,117,118,119,120],"Urinary Incontinence","Daytime Wetting","Urination Disorders","Urologic Diseases","Lower Urinary Tract Symptoms","Urological Manifestations","Elimination Disorders","Behavioral Symptoms",[122,123,124,125],"Voided Urinary Microbiota","Perineal Microbiota","Fecal Microbiota","Illumina MiSeq Sequencing","2026-04-15",{"date":128,"type":32},"2026-04-17",{"date":130,"type":32},"2022-12-14",{"date":132,"type":21},"2028-06",{"name":38,"class":39},4,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":106,"sex":17,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":76,"phases":146,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":134},"100515295","brain-activity-among-children-with-overactive-bladder-and-daytime-urinary-incontinence-and-healthy-children-100515295","NCT05989646","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children, and Modulation of Brain Activity by Transcutaneous Electrical Nerve Stimulation - a Functional Magnetic Resonance Imaging Study","Inclusion Criteria:\n\n* Overactive Bladder as per International Children's Continence Society criteria (cases only).\n* At least 2 incontinence episodes per week (cases only).\n* No urinary tract symptoms (healthy participants only).\n* More than 3 daily urinations.\n* Normal clinical examination.\n\nExclusion Criteria:\n\n* Known urogenital abnormality affecting the lower urinary tract function.\n* Prior surgery in the urinary tract (except circumcision).\n* Known neurological diseases or prior cerebral surgery.\n* Known neuropsychiatric disorders or suspicion of those by screening.\n* Treatment with pharmacological agents affecting the brain function.\n* Prior treatment with Enuresis Alarm or Transcutaneous Electrical Nerve Stimulation.\n* Prior or current treatment with mirabegron or oxybutynin.\n* Current urinary tract infection.\n* Current constipation according to Rome IV-criteria or faecal incontinence.\n* Claustrophobia.\n* Metallic items in the body contraindicating MRI-scans.\n* Abnormal uroflowmetry (healthy participants only).","6 Years","14 Years",{"count":145,"type":21},65,[147],"NA","The aim of this study is to investigate whether the activity in brain areas controlling the bladder is different among children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the aim is to investigate if sacral transcutaneous electric nerve stimulation (TENS) has a central mechanism of action. Children with OAB and DUI will be recruited from involved pediatric departments, and functional magnetic resonance imaging (fMRI) will be performed before and after 10 weeks of sacral TENS. In healthy children without bladder symptoms, only the baseline fMRI will be performed.",[113,114,115,150,116,117,118,120,151,119],"Urination Involuntary","Mental Disorders",[153,154,155,156],"Transcutaneous Electrical Nerve Stimulation","TENS","Functional Magnetic Resonance Imaging","fMRI",{"date":158,"type":32},"2026-04-20",{"date":160,"type":32},"2021-05-05",{"date":162,"type":21},"2027-12",{"name":38,"class":39},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":106,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":76,"phases":174,"briefSummary":175,"conditions":176,"keywords":182,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":40},"100573381","impact-of-screening-and-multicomponent-exercise-on-fall-rates-fractures-and-cardiovascular-health-in-diabetes-100573381","NCT06745544","Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes","Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes: Protocol for a Randomized Control Trial: DIACTIVE","DiaACTIVE","Inclusion Criteria:\n\n1. Men and women with either T1D or T2D with a minimum of 65 years of age with no upper limit.\n2. Living in their own home\n3. A diagnosis of diabetes at least one year prior to inclusion of the study to avoid honeymoon diabetes.\n4. Signed the informed consent.\n\nExclusion Criteria:\n\n1. No previous experience with rhythm-based multitask exercise.\n2. Having significant neurological diseases (e.g., Parkinson's and Multiple Sclerosis), vestibular diseases, or orthopedic surgeries (e.g., hip\u002Fknee replacement) affecting their ability to participate in the study.\n3. Having severely impaired cognitive function, defined as a score below 8 on the cognitive assessment \"the short orientation-memory-concentration test.\"\n4. Being fully dependent on walking aids.\n5. Pregnancy or breast feeding\n6. Active malignancy or terminally ill.\n7. Not being able to understand Danish written and\u002For verbally.\n8. Participating in other interventional clinical studies within the last six months\n9. People with a weekly exercise activity above 5 hours a week",{"count":173,"type":21},490,[147],"The DIACTIVE study is a randomized controlled trial with a 5- year follow-up designed to evaluate the impact of comprehensive screening and multicomponent interventions on fall prevention, bone health, nerve function and cardiovascular outcomes in people with diabetes aged 65 years and older on the short and longer term. Diabetes significantly increases risks of falls, fractures, and cardiovascular disease, yet these areas remain underexplored in clinical research. This trial addresses these gaps with a novel, multidimensional approach.\n\nParticipants undergo extensive baseline assessments, including fall risk stratification, bone mineral density measurements via DXA scans, neuropathy evaluations, and cardiovascular profiling. Based on these evaluations, participants are allocated to risk-based intervention arms. The study's centerpiece is the RYMA and ADL exercise program, a tailored cognitive-motor training regimen integrating strength, balance, and executive function exercises with music-based coordination tasks. Pharmacological treatments for osteoporosis and optimization of cardiovascular risk profiles (e.g., SGLT2 inhibitors, GLP-1 agonists) are also incorporated.\n\nPrimary outcomes focus on reducing fall rates by at least 30%, improving bone density, mitigating fracture risks, enhancing nerve function, and lowering cardiovascular event rates. Secondary endpoints explore mechanisms underlying fall reduction, quality of life improvements, and adherence to interventions. Advanced methodologies such as gait analysis, seismocardiography, and magnetic resonance imaging (MRI) provide detailed insights into the intervention's effects. Follow-ups at 26 weeks, 52 weeks, 2 years, and 5 years ensure long-term efficacy evaluation.\n\nThis trial is conducted at Steno Diabetes Center North and involves interdisciplinary collaboration. By addressing key complications of diabetes through integrated care, the study aims to improve patient outcomes and inform future healthcare strategies for older people with diabetes.",[177,178,179,180,181],"Type 2 Diabetes","Osteoporosis","Diabetic Neuropathies","Fall Prevention","Cardiovascular Diseases",[183,184,185,186,187,188,189,190,191,192],"Diabetes","T1D","T2D","RYMA","Falls","Neuropathy","CVD","Diabetic Complications","Bone health","Fractures","2026-04-14",{"date":128,"type":32},{"date":196,"type":32},"2025-10-01",{"date":198,"type":21},"2027-12-31",{"name":38,"class":39},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":76,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":40},"100530324","the-intelligent-diabetes-telemonitoring-using-decision-support-to-treat-patients-on-insulin-therapy-100530324","NCT06185296","The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy","The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Trial: Study Protocol for a Randomized Controlled Trial","DiaTRUST","Inclusion Criteria:\n\n* Adults ≥ 18 years.\n* Diagnosis of T2D for at least 12 months prior to the day of screening.\n* Patients who are being treated with insulin or about to start insulin treatment (insulin naïve) willing to travel to trial site in North Denmark to attend in-person visits.\n* Have internet at home, have MitID, and willingness to use a smartphone and the other devices used in the trial\n* Signed informed consent.\n* Ability to understand and read Danish.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Major surgery is planned during the trial period.\n* Cancer diagnosis within five years prior to inclusion.\n* Participation in other interventional trials.\n* Limited literacy affecting the use of trial devices.\n* Patient who has worn a CGM monitor less than 6 months prior to the trial.\n* Terms that, in the opinion of the sub-investigator or investigator, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate.\n* Patients treated with mixed insulin.",{"count":209,"type":21},51,[147],"The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for three months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms in the management of insulin treatment.",[213],"Type 2 Diabetes Treated With Insulin",[183,215,216,217,218,219,220,221,222,223],"Insulin","Telemedicine","Telehealth","Telemonitoring","CGM","Wearable devices","Adherence","Decision support","Algorithms","2026-02-05",{"date":226,"type":32},"2026-02-09",{"date":228,"type":32},"2025-11-15",{"date":230,"type":21},"2026-09",{"name":38,"class":39},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":240,"targetDuration":4,"studyType":76,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":40},"100509478","phase-4-lithium-versus-cariprazine-in-the-acute-phase-treatment-of-bipolar-depression-duag9-100509478","NCT05913947","Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)","Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression: a Pragmatic Head-to-head Open, Randomized Multicenter Study: The 9th Study of the Danish University Antidepressant Group (DUAG 9)","DUAG9","Inclusion Criteria:\n\n* A diagnosis of bipolar disorder, type 1 or type 2, and a current episode of depression according to DSM-5\n* Severity of depression: A score of at least 21 on the self-reported Major Depression Inventory (MDI).\n* No start or dose increase of psychotropic medication (except for benzodiazepines and benzodiazepine-like drugs (zopiclone, zolpidem, and melatonin)) in the two weeks prior to inclusion.\n* No new start of formalized psychotherapy sessions, excluding psychoeducation, during the 4 weeks prior to inclusion.\n* Age criteria: Subjects must be at least 18 years old and below 65 at the time of randomization.\n* The duration of the current depressive episode must be between 4 and 52 weeks as judged by the investigator at the time of randomization.\n* Clinical uncertainty regarding which of the alternatives, cariprazine and lithium, would be the better choice in the specific case.\n* Female participants should be sterile or non-fertile or, in case of being fertile, they must have a negative pregnancy test AND use safe anticonception.\n* Signed document of informed consent.\n\nExclusion Criteria:\n\n* Prior or ongoing acute treatment of a depressive episode lasting \\> 14 days with either lithium or cariprazine as judged by the investigator.\n* ECT within the current depressive episode.\n* A score of MAS \\> 6.\n* A diagnosis of dementia.\n* High risk of non-adherence at the investigator's discretion.\n* Not understanding the Danish language as judged by the investigator\n* Psychiatric coercion in the form of forced admission or detainment OR sentence to forensic psychiatric care.\n* Presence of clinically relevant delusions, hallucinations or other psychotic symptoms as judged by the investigator.\n* Suicidality according to C-SSRS with a positive response to question 4 or 5 or upon investigator's discretion.\n* Medical conditions like cancer, kidney failure, epilepsy, deep brain stimulation device, or other medical conditions interfering with study the outcome and safety as judged by investigator's discretion.\n* Current harmful use or dependency of alcohol or drugs according to DSM-5.\n* Known allergy to any of the substances in the study medication.",{"count":241,"type":21},122,[78],"The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease.\n\nThe main question it aims to answer is:\n\nDifference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6)\n\nParticipants will be randomized to treatment with either lithium or cariprazin.\n\n* Will meet for interview and ratings 4 times during study period.\n* In two meetings, there will be made blood samples and ECG. At one meeting also a Urine sample.\n* Will be contacted for telephone interviews at 6 occasions.",[245],"Depression, Bipolar","2026-01-19",{"date":248,"type":32},"2026-01-21",{"date":250,"type":32},"2022-12-13",{"date":252,"type":21},"2028-09-02",{"name":38,"class":39},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":262,"targetDuration":4,"studyType":76,"phases":264,"briefSummary":265,"conditions":266,"keywords":273,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":40},"100613187","improving-treatment-for-depression-in-general-practice-using-a-step-by-step-care-plan-100613187","NCT07263321","Improving Treatment for Depression in General Practice Using a Step-by-Step Care Plan.","Optimising Treatment for Patients With Depressive Episodes in General Practice Through Algorithm-Based Treatment: A Randomised, Open-label Controlled Trial.","ODEGA","Inclusion Criteria:\n\n1. The participant must be referred to the study with a diagnosis of unipolar depressive disorder, as judge by the GP.\n2. Severity of the depressive episode corresponding to moderate depression, as judged by the GP.\n3. Clinical uncertainty regarding which of the treatments, medication or psychotherapy, would be the better choice in the case concerned.\n4. Age criteria: Participants must be at least 18 years old and no more than 65 years old at the time of randomisation.\n5. The participant must be a patient in general practice.\n6. Participants must be able to participate in virtual meetings (e.g. by phone or computer) and have e-Boks.\n7. The participant must be willing to receive psychotherapy by a psychologist and\u002For medication.\n8. Must have signed the document of informed consent.\n\nExclusion Criteria:\n\n1. Misuse of substances that might influence the study, as judged by the investigator.\n2. Difficulty in understanding the Danish language, as judged by the investigator.\n3. A diagnosis of dementia.\n4. Medical conditions that might interfere with the study outcome or safety, judged so by the investigator.\n5. Pregnancy.\n6. High risk of non-adherence at the investigator's discretion.\n7. Suicidality: according to C-SSRS with a positive response to question 4 or 5 within the last three months or upon investigator's discretion.\n8. No current medical or psychotherapy treatment initiated within the last 4 weeks prior to screening.",{"count":263,"type":21},171,[147],"The goal of this clinical trial is to compare three different treatments for depression in patients with moderate depression in General Practice, aged 18-65 years.\n\nWe wish to investigate the effect of the treatment approaches, and 171 patients will be included in the trial. The participants will be randomised to one of the following three treatments:\n\n1. Standard treatment provided by a general practitioner (i.e. the general practitioner treats the patient as he\u002Fshe would normally do, when treating a patient with depression).\n2. Standard treatment provided by a psychologist in the form behavioural therapy (i.e. the psychologist treats the patient as he\u002Fshe would normally do, when treating a patient with depression).\n3. A step-by-step treatment plan carried out by a general practitioner. The plan includes pre-determined follow-ups and a pre-determined, structured plan for which medications to use and when to increase dose or switch medication.\n\nThe hypothesis is that a structured and step-by-step treatment approach regarding patients with depression, treated in general practice, is more effective than standard treatment provided by a general practitioner and a psychologist.\n\nAll the participants will:\n\n1. Receive one of the three treatments for 12 weeks.\n2. Have meetings with the project staff every 4 weeks (week 0, 4, 8 and 12) were rating scales will be completed, e.g. a rating scale to measure progress or deterioration in the participant's depression.",[267,268,269,270,90,271,272],"Depressive Disorder","Depression - Major Depressive Disorder","Depressive Disorder, Major Depressive Disorder","Depressive Disorders","Depressive Episodes","Depressive Episode",[274,275,276,277,278,279,280,281],"Treatment for depressive disorder in General Practice","Algorithm-based treatment in General Practice","Algorithm-guided treatment in General Practice","Algorithm-based treatment for depression in General Practice","Algorithm-based treatment for depressive disorder in General Practice","Algorithm-based treatment for depressive episodes in General Practice","Algorithm-guided treatment for depressive episodes in General Practice","Optimising treatment for depressive episodes in general practice","2025-12-04",{"date":284,"type":32},"2025-12-10",{"date":286,"type":21},"2025-12",{"date":97,"type":21},{"name":38,"class":39},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":76,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":134},"100563841","a-national-study-examining-the-most-effective-drainage-method-after-burr-hole-evacuation-of-chronic-subdural-hematoma-100563841","NCT06621407","A National Study Examining the Most Effective Drainage Method After Burr Hole Evacuation of Chronic Subdural Hematoma","Active 24 Hours Subperiostal vs. 24 Hours Passive Subdural Drainage Following Burr Hole Evacuation of Chronic Subdural Hematoma (the SUPERDURA Trial) - Protocol for a Nationwide Randomized Clinical Non-inferiority Trial","SUPERDURA","Inclusion Criteria:\n\n* Adult patients (≥ 18 years).\n* Patients with symptomatic CSDH confirmed on brain CT- or magnetic resonance imaging (MRI), admitted to a Danish neurosurgical department for surgical treatment.\n* Patients undergoing a single burr-hole evacuation.\n* Informed written and oral consent is taken prior to surgery.\n\nExclusion Criteria:\n\n* Patients who are mentally incapacitated\n* Patients with known abnormalities in their cerebrospinal fluid (protein and glucose levels, cell count, and type)\n* Patients with changes or abnormalities in their normal cerebrospinal fluid dynamics, e.g., obstructive hydrocephalus, normal pressure hydrocephalus, intracranial hypotension, and ventricular peritoneal shunt.\n* Patients with additional\u002Fpreviously intracranial pathology that requires\u002Fhas required neurosurgical treatment (e.g., brain tumor, vascular malformation, abscess).\n* Patients with recurrent CSDH or with previous craniotomy or other transcranial surgery (for any reason)\n* Patients unable to give consent prior to surgery",{"count":298,"type":21},354,[147],"Chronic subdural hematoma (CSDH) is a common disease. The main treatment is neurosurgical evacuation and subsequent hematoma drainage. However, consensus on the optimal drain placement site, and whether the drainage should be active or passive, is lacking.\n\nThe aim of the current study is to test the hypothesis that 24 hours active subperiosteal drainage is non-inferior to 24 hours passive subdural drainage after single burr hole evacuation of a unilateral CSDH.\n\nThe study is a multicenter randomized non-inferiority trial encompassing all neurosurgical units in Denmark.\n\nAdult patients with symptomatic CSDH admitted to a Danish neurosurgical unit for single burr hole evacuation will be screened for inclusion. Patients who are not able to give informed consent, and patients with recurrent CSDH, known cerebrospinal fluid abnormalities, and other known brain pathologies will be excluded. Patients with bilateral CSDH will be registered as one case and treated similarly on both sides.\n\nBefore surgical hematoma evacuation patients will be randomized to 24-hour passive subdural drainage or 24-hour active subperiosteal drainage.\n\nThe patients included and the two study statisticians will be blinded. The primary outcome is a composite outcome of 90-day mortality and symptomatic CSDH recurrence.\n\nSecondary outcomes are 90-day simplified modified Rankin score (smRSq), and complications related to surgery or occurring during admission, including intracerebral hemorrhage due to misplaced drains, acute subdural hematoma, tension pneumocephalus, wound infection, drain seepage, subperiosteal hematoma, thromboembolic events, infections and seizures.\n\nSample size simulations of non-inferiority with a threshold of 7% increased relative risk show that a total of 354 participants will be required to demonstrate a relative risk reduction of recurrent CSDH and mortality of 30% for the cohort receiving active subperiosteal drainage given a stable power above 80% with an alpha of 5%. The study inclusion period is estimated to last 2 years.\n\nEthics approval for inclusion of competent patients has been obtained (N-20240009).",[302,303,304,305,306,307,308],"Chronic Subdural Hematoma","Surgical Procedures, Operative","Recurrence","Mortality","Drainage","Drainage\u002FMethods","Drainage Procedure","2025-11-20",{"date":311,"type":32},"2025-11-25",{"date":313,"type":32},"2025-09-01",{"date":315,"type":21},"2027-11",{"name":38,"class":39},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":324,"minAge":18,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":40},"100452287","association-between-plasma-level-of-mannose-binding-lectin-and-human-reproduction-100452287","NCT05169541","Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction","Is Plasma Level of Mannose Binding Lectin Associated With Reproductive Failure?","Inclusion Criteria:\n\nfulfil one of the following:\n\n* 3 consecutive pregnancy losses after spontaneous conception\n* 3 consecutive pregnancy losses after assisted reproductive technology treatment (ART) including IVF, ICSI and FET\n* 3 failed embryo transfers characterized by no achieved pregnancy (after 3 cycles with minimum 1 embryo transfer of a good-quality embryo in each cycle.)\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* AMH \\\u003C4.0 pmol\u002Fl unless donor egg in previous cycles\n* Significant uterine malformation\n* Known endometrial pathologies including intrauterine endometriosis, adenomyosis, hyperplasia or polyps\n* Known chromosomal abnormalities\n* Pregnancy \\>9 weeks of gestation at the time collecting the blood sample","FEMALE","41 Years",{"count":327,"type":21},500,"A low plasma level of mannose binding lectin (p-MBL) is associated with unexplained recurrent pregnancy loss (RPL), but it is not investigated if it is associated with unexplained reproductive failure in general, including recurrent implantation failure (RIF) after assisted reproductive technology (ART) (including IVF, ICSI and FET), recurrent pregnancy loss (RPL) after spontaneous conception, and RPL after ART.",[330,331,332,333,334,335,336],"Mannose-Binding Lectin Deficiency","Recurrent Pregnancy Loss","Recurrent Implantation Failure","Infertility","Habitual Abortion","Recurrent Miscarriage","Recurrent Spontaneous Abortion",{"date":338,"type":32},"2025-11-24",{"date":340,"type":32},"2016-01-01",{"date":342,"type":21},"2026-11-30",{"name":38,"class":39},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":352,"conditions":353,"keywords":358,"overallStatus":364,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":371,"locationsCount":66},"100607238","dual-energy-ct---a-tool-for-delineation-of-tumor-and-organs-at-risk-in-radiotherapy-100607238","NCT07185958","Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy","DART","Inclusion Criteria:\n\n* ECOG performance status (PS) 0-2\n* Assessed to be able to complete the protocol scanning regime\n* Referred for RT\n* For head and neck cancer patients, a PET\u002FCT scan must have been performed during the diagnostic evaluation for cancer\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Previous RT in the same anatomical area now referred for RT\n* Previous surgery in the same anatomical area now referred for RT\n* Participation in conflicting protocols\n* If relevant for the protocol scanning regime: Allergic to contrast agent\n* If relevant for the protocol scanning regime: Contraindication to iodine-based contrast agent for CT (as determined by the physician)\n* If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician)\n* If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.)\n* Incapable of understanding the patient information",{"count":75,"type":21},"The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and\u002For contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H\\&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H\\&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)\u002FCT scan currently used in clinical practice.",[354,355,356,357],"Brain Metastases","Bone Metastases","Head and Neck Cancer","Lung Cancer",[359,360,361,362,363],"tumor delineation","organs at risk delineation","dual-energy CT","DECT","radiotherapy","NOT_YET_RECRUITING","2025-09-15",{"date":367,"type":32},"2025-09-22",{"date":367,"type":21},{"date":370,"type":21},"2028-03-21",{"name":38,"class":39},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":364,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":389,"leadSponsor":391,"locationsCount":40},"100605673","prevalence-of-anticholinergics-in-geriatric-patients-with-acute-functional-deterioration-100605673","NCT07165574","Prevalence of Anticholinergics in Geriatric Patients With Acute Functional Deterioration","Inclusion Criteria:\n\n* patients seen by the Subacute outpatient geriatric clinic at Aalborg University hospital, Denmark, between 2024 and 2025.\n* Consecutive sampling starting with the most recent patient chart and going backwards.\n* Inclusion is based on chart review and all patients are therefore included consecutively.\n\nExclusion Criteria:\n\n* None",{"count":379,"type":21},100,"This study investigates the anticholinergic burden on patients seen in the Subacute mobile outpatient geriatric clinic in Aalborg, Denmark, between the years of 2024 and 2025.\n\nThe age demographic in Denmark and multiple other countries is changing rapidly, with more old and very old individuals as a result. As humans become older, they tend to accumulate more illnesses, and the risk of polypharmacy increases. There is a wide selection of medicine that affect the binding of acetylcholine to the muscarinic receptors, which is either the intended function of the pharmacological product or a side effect.\n\nSince there is no built-in feature in computer systems used by doctors to calculate the cumulative anticholinergic burden, it is often not recognized, thus not reflected upon.\n\nThis raises concerns about potential central and peripheral side effects, such as altered mental status, visual disturbances, tachycardia, urinary and fecal retention, dry skin etc.\n\nThe study aims to determine the prevalence of anticholinergics in the last 100 patients seen by the Subacute mobile outpatient geriatric clinic in Aalborg University Hospital. The patients are placed in municipal extended-care facilities. Furthermore, the study will investigate the prevalence of anticholinergic side effects concerning the burden on this population.\n\nThe study is a retrospective chart review of patient charts from the years of 2024 and 2025, analyzing patient characteristics, comorbidities, medication lists, and calculating the anticholinergic burden through the ACB calculator.",[382,383,384],"Frailty in Older Adults","Functional Decline","Anticholinergic Syndrome","2025-09-09",{"date":387,"type":32},"2025-09-10",{"date":313,"type":21},{"date":390,"type":21},"2027-01-01",{"name":38,"class":39},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":40},"100606273","assessing-the-quality-of-telephone-follow-up-after-spine-surgery-100606273","NCT07173413","Assessing the Quality of Telephone Follow-Up After Spine Surgery","Evaluating the Quality of Telephone Follow-Up After Spine Surgery: A Non-Inferiority Study","Inclusion Criteria:\n\n* Patients who have undergone lumbar spine surgery at the Department of Neurosurgery, Aalborg University Hospital, Aalborg, Denmark.\n* Able to read and understand Danish.\n\nExclusion Criteria:\n\n* Withdrawel of consent",{"count":400,"type":21},200,"The aim of this study is to investigate whether the quality of physiotherapy follow-up after spinal surgery can be maintained when conducted by telephone rather than in-person. The study is motivated by the desire to save healthcare resources and reduce the environmental impact of patient travel. Data from patient records, including age, sex, surgery procedure, use of pain medication, and time spent on either phone or in-person follow-ups, will be collected to evaluate whether telephone-based follow-up is an effective and sustainable alternative for post-operative care.",[403],"Low Back Pain",[405,406],"low back pain","surgery","2025-09-08",{"date":365,"type":32},{"date":410,"type":32},"2025-06-12",{"date":412,"type":21},"2026-02-01",{"name":38,"class":39},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":76,"phases":424,"briefSummary":426,"conditions":427,"keywords":433,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":40},"100576806","phase-2-the-diagnostic-accuracy-and-clinical-value-of-fapi-pet-in-pleural-mesothelioma-100576806","NCT06790082","The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma","FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation","FAPI-PM","Inclusion Criteria:\n\n* Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy.\n* Undergone\u002Fundergoing FDG PET\u002FCT as part of the diagnostic workup of a suspicious PM lesion.\n* Considered physically and mentally able to participate in the research project.\n* Understands the study subject information and able to consent to project participation.\n* 18-years or older\n\nExclusion Criteria:\n\n* Patients with an imminent need for surgery or in an emergency\n* Known concurrent other malignancy with active treatment within the last 1 year; non-melanoma skin cancer and cervical cancer in situ are exempt.\n* Pregnant or breastfeeding women.\n* Fertile women (women of childbearing potential) who could - theoretically - be pregnant (i.e., unknown pregnancy status).\n\nFertile women will be tested for pregnancy (by urine humane choriogonadotropin (HCG) or serum HCG) within 48h before FAPI PET\u002FCTs, both at primary staging and restaging. Study subjects can participate in the study if the pregnancy test is negative (i.e., not pregnant).\n\n* Subjects unable to undergo PET\u002FCT: e.g., weighing more than 180 kg (weight limit scanner), unable to fit within the imaging gantry, inability to remain still for the duration of the examination, or with known severe claustrophobia unresponsive to oral anxiolytics or severe fear of needles.\n* Subjects with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease the reliability of data, achievement of study objectives or completing the study.\n* History of allergic reactions \u002F hypersensitivity attributed to \\[18F\\]FDG or FAPI-tracers.",{"count":423,"type":21},70,[425],"PHASE2","Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET\u002FCT at primary staging.\n\nThe FAPI PET\u002FCT results will be compared to conventional imaging (including FDG PET\u002FCT). The diagnostic accuracy will be determined with histopathology as reference standard.\n\nFor patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET\u002FCT and an additional FDG PET\u002FCT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET\u002FCT in response evaluation will be investigated.\n\nAll study specific analyzes will be blinded and will not influence the patient management \u002F treatment.",[428,429,430,431,432],"Pleural Mesothelioma","Pleural Diseases","Cancer","FAPI","Fibroblast Activation Protein Inhibitor",[431,434,435,428,436],"68Ga-FAPI-46","PET\u002FCT","FDG PET\u002FCT","2025-07-01",{"date":439,"type":32},"2025-07-03",{"date":441,"type":32},"2025-01-29",{"date":443,"type":21},"2037-04-30",{"name":38,"class":39},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":76,"phases":454,"briefSummary":455,"conditions":456,"keywords":458,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":40},"100518942","implementation-of-a-structured-post-pulmonary-embolism-follow-up-model-100518942","NCT06037096","Implementation of a Structured Post-pulmonary Embolism Follow-up Model","Implementation of a Structured Post-pulmonary Embolism Follow-up Model in a Danish Hospital Setting","Inclusion Criteria:\n\n* adult patients (≥18 years)\n* CT-verified diagnosis of PE\n\nExclusion Criteria:\n\n* patients who are not living in Denmark on the extraction date\n* patients with a active cancer",{"count":453,"type":21},2000,[147],"Venous thromboembolism (VTE), clinically presenting as deep vein thrombosis or pulmonary embolism (PE) is the third most frequent cardiovascular disease and is associated with substantial short- and long-term morbidity and mortality and high costs of care. In addition negative physical and mental complications following VTE are common. However in terms of PE, there are no structured follow-up programs in Denmark and there is considerable variation in practice patterns of post-PE management both within and between countries.\n\nThis project aims to develop, test and implement a structured follow-up care model for patients with PE (The Attend-PE model). This project is a pre-post intervention study and will estimate the effectiveness of implementing the structured follow-up care model on a national level.",[457],"Pulmonary Embolism",[459,460,461,462,463],"Implementation","Health related quality of life","Intervention","Pulmonary embolism","Health care model","2025-06-10",{"date":466,"type":32},"2025-06-13",{"date":468,"type":32},"2022-03-15",{"date":470,"type":21},"2026-10",{"name":38,"class":39},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":40},"100515481","wearable-sensors-for-monitoring-recovery-after-total-knee-arthroplasty-100515481","NCT05992064","Wearable Sensors for Monitoring Recovery After Total Knee Arthroplasty","Investigating the Potential of Wearable Sensors for Monitoring the Postoperative Recovery of Total Knee Arthroplasty Patients: A Protocol for Prospective Longitudinal Observational Study","Inclusion Criteria:\n\n* Patients diagnosed with knee OA and scheduled to undergo unilateral TKA at Aalborg University Hospital, Farsø.\n\nExclusion Criteria:\n\n* Daily pain (numeric rating scale (NRS) ≥ 4) or severe OA in the contralateral knee (KL-IV)\n* Daily pain (NRS ≥ 4) or severe OA in the spine and other lower limb joints\n* BMI \\> 35 kg\u002Fm2\n* Recent surgery in the spine or lower limbs (\\\u003C 6 months)\n* Neurological movement disorders\n* Inflammatory arthritis\n* Patients who are not smartphone users\n* Frail patients with clinical frailty scale (CFS)10 ≥ 5\n* Residents of nursing homes\n* Patients dependent to walking aids for ambulation\n* Patients with dementia or memory problems\n* Patients with skin sensitivity or issues at the location of the plasters.",{"count":480,"type":21},30,"The goal of this observational study is to investigate the potential of wearable sensors for monitoring the postoperative recovery of patients after TKA.\n\nThe main question the study aims to answer is:\n\n• whether alterations in gait characteristics and the changes in PA levels measured by wearable PA trackers can accurately reflect a patient's postoperative recovery status and provide clinically relevant information to aid their management.\n\nParticipants will wear PA trackers during the perioperative period of TKA (2 weeks before until 3 months after, and then agin for 2 weeks one year after the surgery) and we will analyze their gait and PA and correlate them with their recovery after surgery.",[483],"Arthroplasty, Replacement, Knee","2025-04-08",{"date":486,"type":32},"2025-04-10",{"date":488,"type":32},"2024-03-12",{"date":490,"type":21},"2026-10-01",{"name":38,"class":39},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":499,"minAge":18,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":76,"phases":502,"briefSummary":503,"conditions":504,"keywords":509,"overallStatus":364,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":66},"100579662","treatment-of-bulbar-urethral-strictures-with-optilume-drug-coated-balloons-in-an-untreated-population-100579662","NCT06827210","Treatment of Bulbar Urethral Strictures With Optilume Drug-Coated Balloons in an Untreated Population","FIRST-CARE","Inclusion Criteria:\n\n* Male patients aged 18 years or older.\n* Diagnosed with a treatment-naive, single bulbar urethral stricture.\n* Stricture length ≤3 cm.\n* Eligible for local treatment with paclitaxel.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Female (chromosomal) sex.\n* History of prior urethral stricture or prior treatment thereof.\n* History of hypospadias repair.\n* History of genital lichen sclerosis.\n* Active or unresolved confounding etiology, including bladder neck contracture, neurogenic bladder, known or being evaluated for symptomatic benign prostatic hyperplasia (BPH) or surgical treatment for BPH within the last 5 years.\n* Known allergy or hypersensitivity to paclitaxel or any component of the Optilume DCB.\n* Known peripheral artery disease.\n* Severe comorbidities with an American Society of Anesthesiologists (ASA) score of 4 or higher.\n* Patients unable to comply with follow-up protocols or provide informed consent.","MALE",{"count":501,"type":21},140,[147],"This randomized controlled trial investigates the effectiveness and safety of the Optilume® drug-coated balloon (DCB) compared to standard direct visual internal urethrotomy (DVIU) in the treatment of bulbar urethral strictures. The primary objective is to assess freedom from repeat intervention at 12 months. Secondary objectives include evaluating urethral patency, urinary symptoms, and sexual function through objective measures (Qmax, PVR, cystoscopy) and patient-reported outcomes (USS-PROM, IPSS, IIEF-5). The study will recruit 140 participants across multiple sites, with follow-ups conducted at 6 and 12 months. This trial seeks to provide evidence for Optilume DCB as a safe and effective alternative to standard treatment.",[505,506,507,508],"Urethral Stricture","Urethral Stricture, Anterior","Urethral Stricture, Male","Urethral Stricture Less Than 2 cm",[505,510,511,512,513],"Optilume Drug-Coated Balloon","DVIU","Urology","Patient-Reported Outcomes","2025-02-13",{"date":516,"type":32},"2025-02-14",{"date":518,"type":21},"2025-02-07",{"date":520,"type":21},"2027-07",{"name":38,"class":39},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":40},"100406027","specific-methylation-profiles-in-hnscc-100406027","NCT04567056","Specific Methylation Profiles in HNSCC","Validation of Specific Methylation Profiles Ind Head and Neck Cancer - a Cohort Study","Cancer group:\n\nInclusion Criteria:\n\n* Written informed consent\n* Verified head and neck squamous cell carcinoma\n\nExclusion Criteria:\n\n* Other active cancer\n* Uncontrolled comorbidity\n* Unable to give informed consent\n\nControl group:\n\nInclusion Criteria:\n\n* Written informed consent\n* Normal ENT-examination\n\nExclusion Criteria:\n\n* Other active cancer\n* Uncontrolled comorbidity\n* Unable to give informed consent",{"count":530,"type":21},300,"In the study, N-20190047, the investigators aim to define specific methylation patterns in a group of patients with head and neck squamous cell carcinomas.\n\nWith this study the investigators aim to validate these findings in a larger cohort.",[533],"Head and Neck Squamous Cell Carcinoma",[535,536,537,538],"Head and neck cancer","Squamous Cell carcinoma","Methylation","DNA","2025-02-05",{"date":518,"type":32},{"date":542,"type":32},"2020-09-16",{"date":544,"type":21},"2026-06-01",{"name":38,"class":39},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":552,"enrollmentInfo":553,"targetDuration":4,"studyType":76,"phases":555,"briefSummary":556,"conditions":557,"keywords":560,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":40},"100546539","structural-and-functional-networks-in-als-an-insight-into-pseudobulbar-affect-100546539","NCT06396260","Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect","Inclusion Criteria:\n\n* Diagnosed with ALS in the last 6 months according to Gold Coast Criteria\n\nExclusion Criteria:\n\n* \\- Lack of ability to answer survey through own ability or through a surrogate, for example by hand controlled, eye-controlled computer and\u002For tablet, or through telephone interview.\n* Lack of ability to cooperate.\n* Pregnancy\n* Drug addiction defined as the non-prescribed use of cannabis, opioids, or other narcotics.\n* Alcohol addiction defined as over 21 units weekly.\n* Lesional neurological diseases, such as stroke, tumor or multiple sclerosis\n* Epilepsy\n* Neurodegenerative diseases other than ALS\n* Severe psychiatric disease such as major depression disorder, bipolar disease or schizophrenia\n* Contraindication for MRI and MEG scan according to hospital guidelines\n* Severe liver or kidney disease\n* Dysregulated heart disease\n* Ongoing treatment with any antidepressants or any antipsychotics at recruitment.\n* Diagnosed with frontotemporal dementia.","90 Years",{"count":554,"type":21},50,[147],"The investigators aim to elucidate characteristics of structural and functional brain connectivity in patients with amyotrophic lateral sclerosis (ALS) and pseudobulbar affect (PBA) using diffusion kurtosis imaging (DKI) and magnetoencephalography (MEG).",[558,559],"Amyotrophic Lateral Sclerosis","Pseudobulbar Affect",[561,562,563],"Diffusion Kurtosis Imaging","Magnetoencephalography","Connectivity","2025-01-28",{"date":441,"type":32},{"date":567,"type":32},"2024-05-26",{"date":64,"type":21},{"name":38,"class":39},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":590,"locationsCount":40},"100487198","proteomics-in-small-cell-lung-cancer-100487198","NCT05623956","Proteomics in Small Cell Lung Cancer","Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer","SCLC-OMICS","Inclusion Criteria:\n\n* Written and signed informed consent\n* Histopathologically and\u002For cytologically newly-diagnosed SCLC\n* Measurable disease on CT scans\n* Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide\n\nExclusion Criteria:\n\n* Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ\n* Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ\n* Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)\n* Treatment with any other investigational agent",{"count":554,"type":21},"The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.",[581],"Small Cell Lung Cancer",[583,584],"Proteomics","Biomarkers",{"date":586,"type":32},"2025-01-31",{"date":588,"type":32},"2023-03-01",{"date":286,"type":21},{"name":38,"class":39},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":76,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":614,"locationsCount":40},"100534182","long-term-home-based-exercise-for-patients-with-copd-the-copdtoparis-project-100534182","NCT06235502","Long-term Home-based Exercise for Patients With COPD: the COPDtoParis Project","A Cluster Randomised Controlled Trial on the Effects of Long-term Home-based Exercise for Patients With Chronic Obstructive Pulmonary Disease With Recent Exacerbation: the COPDtoParis Project","COPDtoParis","Inclusion Criteria:\n\n* Adults at age \\> 18 years old\n* Hospital admission with COPD exacerbation with pre-existing COPD diagnosis\n* Citizens of Aalborg Municipality\n* Able to provide informed consent\n* Accepting of referral to rehabilitation\n\nExclusion Criteria:\n\n* Terminal illness\n* Unstable heart disease, i.e., ischemic heart disease, cardiac rhythm disorders\n* Other conditions preventing participating in cycle exercise, e.g., amputation, regimens or earlier or upcoming surgeries preventing seated position, blindness\n* Inability to understand basic Danish oral and written information or giving informed consent.",{"count":600,"type":21},40,[147],"This randomised controlled trial (RCT) aims to investigate the effect of long-term, interactive home-based cycle-exercise on patients with Chronic Obstructive Pulmonary Disease (COPD) after a COPD exacerbation requiring hospitalisation. The investigators aim to investigate if patients can maintain or improve the effects of pulmonary rehabilitation in terms of walking distance, intensity of COPD symptoms, health related quality of life and Quality Adjusted Life-Years.\n\nParticipants will cycle on a pedal-exerciser in the comfort of staying in the participants' own home, whilst getting visual feedback from the 4Mvideo app. The 4Mvideo technology is a Danish designed software system, where users can cycle forward a recording of a cyclist by treading on a pedal-exerciser, thereby getting some of the experience of a real-life cycling trip at home.\n\nThe investigators will compare the clinical outcomes and daily activity levels with that of a control group consisting of COPD patients.",[604,605,606,607],"Telerehabilitation","COPD","Quality of Life","Mobility Limitation","2024-12-02",{"date":610,"type":32},"2024-12-04",{"date":612,"type":32},"2023-11-01",{"date":313,"type":21},{"name":38,"class":39},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":76,"phases":624,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":40},"100472759","phase-4-a-trial-to-compare-efficacy-and-tolerability-of-plenvu-and-picoprep-as-cleansing-agents-before-colonoscopy-100472759","NCT05436054","A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy","A Randomised Controlled Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy","Inclusion Criteria:\n\n* Ambulant colonoscopy\n* Older than18\n\nExclusion Criteria:\n\n* Younger than 18\n* Known with severe heart failure\n* Known with severe renal failure (eGFR\\\u003C30)\n* Known for colonic stenosis\n* Pregnant or breastfeeding\n* Acute colonoscopy\n* Cancer screening program colonoscopy\n* Mentally retarded\n* Redo colonoscopy of patients included in this study and colonoscopy was canceled because of bad bowel preparation.\n* Patients with Phenylketonuria\n* Patients with Glucose-6-phosphate-dehydrogenase deficiency\n* Patients with colon or rectum resection",{"count":623,"type":21},400,[78],"The trial is about comparing the efficacy of Plenvu with Picoprep. Both are bowel cleansing agents prior to visual examination of the large bowel to exclude cancer disease.\n\n400 patients who are referred for colonoscopy to a single center in North Jutland will be randomised either to Picoprep or Plenvu. These patients will then answer a questionnaire prior to colonoscopy. The questionnaire is about the most common expected side effects and the experience of cleansing og intake of the bowel agents.\n\nThe effect of the two agents will examined using a special scoring system (Harefield) to determine the quality of bowel cleansing. Colonoscopist who evaluate the cleansing is blinded to which agent the patient has taken.",[627],"Colon Disease",[629,630],"colonoscopy","bowel cleansing","2024-11-18",{"date":633,"type":32},"2024-11-19",{"date":635,"type":32},"2022-10-01",{"date":637,"type":21},"2025-12-01",{"name":38,"class":39},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":647,"enrollmentInfo":648,"targetDuration":4,"studyType":76,"phases":650,"briefSummary":651,"conditions":652,"keywords":655,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":669},"100559124","danish-evaluation-of-early-catheter-ablation-for-atrial-fibrillation-in-patients-with-heart-failure-100559124","NCT06560047","Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure","Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure - The DanAblate-HF Trial","DanAblate-HF","Inclusion Criteria:\n\n1. HF patients with AF within the past 12 months\n\n   HF is defined as all of the below (all must apply)\n   * Clinically assessed Heart Failure with Reduced Ejection Fraction (HFrEF)\n   * An indication for initiation or ongoing guideline directed medical therapy for HFrEF, according to current Heart Failure guidelines\n   * LVEF \\\u003C 50% at any point during the past 12 months\n\n   AF is defined as one or more of the following:\n\n   A. Symptomatic AF, documented by ECG, Holter of CIED\n\n   B. Asymptomatic AF with one or more of the following:\n   * Clinical indication for rhythm or rate control (documented by ECG, telemetry, Holter, CIED)\n   * ≥2 ECG detected AF episodes within 3 months (on separate dates)\n   * Holter detected AF with a continuous duration of more than 6 hours\n   * CIED detected AF with continuous duration \\>24 hours\n2. 18 years ≤ Age \\\u003C80 years\n3. Optimal medical therapy for HFrEF or planned\u002Fcurrent uptitration in guideline directed medical therapy for HFrEF\n4. Treatment with anticoagulation for stroke prevention, initiated according to guidelines for treatment of AF\n\nExclusion Criteria:\n\n1. Life-expectancy \\\u003C 1 year\n2. BMI \\> 40\n3. Contraindications or unacceptable side effects to rate limiting drugs AND amiodarone\n4. LA size (indexed for BSA) \\> 60 ml\u002Fm2 (volume) on echo within the last year\n5. Documented persistent\u002Fpermanent AF \\> 1 year\n6. Previous AF ablation\u002Fsurgery\n7. Reversible causes of AF (including, but not limited to, infection within 14 days, untreated thyroid disease, surgery)\n8. Severe valvular disease\n9. Acute myocardial infarction, cardiothoracic surgery or stroke within the past 3 months\n10. Planned cardiothoracic surgery\n11. Listed for heart transplant\n12. Contraindications for anticoagulation therapy or catheter ablation\n13. Severe kidney disease (CKD≥5)\n14. Pregnancy\n15. Patient unwilling to try medical therapy for AF\n16. Patient unwilling\u002Funable to give informed consent for study participation","80 Years",{"count":649,"type":21},1616,[147],"The DanAblate-HF trial will investigate whether early catheter ablation treatment for atrial fibrillation in patients with heart failure is superior to standard treatment.",[653,654],"Atrial Fibrillation","Heart Failure",[656,657,658,659,660],"Heart failure","Atrial fibrillation","Catheter ablation","Treatment","Outcome","2024-08-29",{"date":663,"type":32},"2024-08-30",{"date":665,"type":32},"2024-08-28",{"date":667,"type":21},"2039-08-31",{"name":38,"class":39},6,{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":676,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":678,"enrollmentInfo":679,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":680,"conditions":681,"keywords":685,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":687,"lastUpdatePostDateStruct":688,"startDateStruct":690,"completionDateStruct":692,"leadSponsor":694,"locationsCount":40},"100481218","characterization-and-prediction-of-early-onset-diabetic-peripheral-neuropathy-100481218","NCT05546138","Characterization and Prediction of Early Onset Diabetic Peripheral Neuropathy","Characterization and Prediction of Early Onset Diabetic Peripheral Neuropathy (NeuroPredict)","NeuroPredict","Inclusion Criteria:\n\n* Men and women aged 18-80 years\n* Diagnosed with diabetes (of any type)\n* No clinically established diabetic peripheral neuropathy at inclusion\n\nExclusion Criteria:\n\n* Alcohol or drug abuse within the last year (prior to inclusion)\n* Chemotherapy (prior or within study period) or experimental medicine\n* Severe vitamin deficiencies\n* Inability to understand or comply with the examinations\n* Planned or likely discontinuation of care at Aalborg University Hospital\n* Known hematologic disorders resulting in a markedly reduced ability to stop small bleedings\n* Severe limb ischemia\n* Active diabetic foot ulcers\n* Previous amputations\n* Severe skin diseases or diseases known to cause neural damage\n* Pregnancy at inclusion","60 Years",{"count":400,"type":21},"Predicting early onset neuropathy in people with type 1 diabetes",[682,683,684],"Neuropathy, Diabetic","Small Nerve Fiber Neuropathy","Type 1 Diabetes",[686],"Diabetic neuropathy, Early detection, Clinical Endpoints, Prediction, Risk stratification","2024-06-27",{"date":689,"type":32},"2024-06-28",{"date":691,"type":32},"2023-10-01",{"date":693,"type":21},"2029-12-31",{"name":38,"class":39},""]